Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo [Yahoo! Finance]
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $35.00 to $32.00. They now have a "buy" rating on the stock.
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs [Yahoo! Finance]
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs